Equities

Youcare Pharmaceutical Group Co Ltd

688658:SHH

Youcare Pharmaceutical Group Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)16.55
  • Today's Change0.93 / 5.95%
  • Shares traded3.08m
  • 1 Year change-2.30%
  • Beta1.2304
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy3
Outperform0
Hold0
Sell0
Strong Sell0

Dividends

In 2023, Youcare Pharmaceutical Group Co Ltd reported a dividend of 0.20 CNY, which represents a 81.82% decrease from last year. The analyst covering the company expects dividends of 0.12 CNY for the upcoming fiscal year, a decrease of 40.00%.
Div growth (TTM)-81.82%
More ▼

Earnings history & estimates in CNY

Youcare Pharmaceutical Group Co Ltd reported annual 2023 earnings of 0.41 per share on Feb 23, 2024.
Average growth rate-44.59%
More ▼

Revenue history & estimates in CNY

Youcare Pharmaceutical Group Co Ltd had revenues for the full year 2023 of 4.20bn. This was 7.61% below the prior year's results.
Average growth rate-7.61%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.